Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Richard S. Finn; Stephen L. Chan; Andrew X. Zhu; Jennifer J. Knox; Ann‐Lii Cheng; A.B. Siegel; O. Bautista; P.A. Watson; Masatoshi Kudo

doi:10.1093/annonc/mdw371.105

Related publications

Article2017

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, Masatoshi Kudo

Article2017

KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, A.B. Siegel, O. Bautista, Masatoshi Kudo

Article2017

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, P.A. Watson, Masatoshi Kudo

Article2017

Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Stephen L. Chan, Richard S. Finn, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, A.B. Siegel, O. Bautista, Masatoshi Kudo

Article2019

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho-Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Discussion(0)

Related publications

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).